肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：miRNA-487a促进肝细胞癌增殖与转移

2017-05-28 MedSci MedSci原创

肝细胞癌miRNA-487a增殖转移
关注

肝细胞癌具有高度转移特性，易发生术后复发及转移。但是复发及转移的机制尚未完全明确。CLIN CANCER RES近期发表了一篇文章，研究miR-487a在肝细胞癌增殖及转移中所扮演的角色以及阐明其分子机制。

肝细胞癌具有高度转移特性，易发生术后复发及转移。但是复发及转移的机制尚未完全明确。CLIN CANCER RES近期发表了一篇文章，研究miR-487a在肝细胞癌增殖及转移中所扮演的角色以及阐明其分子机制。

研究纳入198例肝细胞癌样本，分析miR-487a表达与患者临床病理特征及预后的关系。在体外及体内实验中研究miR-487a在肿瘤增殖及转移中所扮演的角色。使用双荧光素酶报告系统分析、染色质免疫沉淀以及免疫组化分析miR-487a上游及下游调节因子。研究结果表明miR-487a上调与肝细胞癌患者不良预后有关。miR-487a通过直接与SPRED2或PIK3R1结合增强肝细胞癌细胞增殖与转移。有趣的是，miR-487a主要通过SPRED2诱导丝裂原活化蛋白酶信号促进肿瘤细胞转移，通过PIK3R1调节的AKT信号途径促进肿瘤细胞增殖。在鼠模型中有效沉默miR-487a可以抑制肝细胞癌进展。

文章最后认为，miR-487a通过与PIK3R1以及SPRED2结合促进肝细胞癌增殖与转移。miR-487a可以作为肝细胞癌的潜在治疗靶点或预后因子。

原始出处：
Rui-Min Chang,Shuai Xiao,et al.miRNA*487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.CLIN CANCER RES.May 2017 doi:10.1158/1078-0432.CCR-16-0851

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978502, encodeId=4ede19e8502f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 01 20:56:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930460, encodeId=8fe2193046008, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 10 18:56:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863275, encodeId=2fe118632e53e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 05 17:56:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204928, encodeId=dd4e20492868, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed May 31 21:41:31 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312292, encodeId=cdf81312292fe, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue May 30 08:56:00 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2018-03-01 qingting

    #细胞癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1978502, encodeId=4ede19e8502f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 01 20:56:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930460, encodeId=8fe2193046008, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 10 18:56:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863275, encodeId=2fe118632e53e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 05 17:56:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204928, encodeId=dd4e20492868, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed May 31 21:41:31 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312292, encodeId=cdf81312292fe, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue May 30 08:56:00 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2018-03-10 smallant2002

    #miR#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1978502, encodeId=4ede19e8502f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 01 20:56:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930460, encodeId=8fe2193046008, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 10 18:56:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863275, encodeId=2fe118632e53e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 05 17:56:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204928, encodeId=dd4e20492868, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed May 31 21:41:31 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312292, encodeId=cdf81312292fe, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue May 30 08:56:00 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2018-03-05 xjy02

    #肝细胞#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1978502, encodeId=4ede19e8502f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 01 20:56:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930460, encodeId=8fe2193046008, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 10 18:56:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863275, encodeId=2fe118632e53e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 05 17:56:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204928, encodeId=dd4e20492868, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed May 31 21:41:31 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312292, encodeId=cdf81312292fe, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue May 30 08:56:00 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2017-05-31 luominglian113

    学习了，谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1978502, encodeId=4ede19e8502f3, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 01 20:56:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930460, encodeId=8fe2193046008, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 10 18:56:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863275, encodeId=2fe118632e53e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 05 17:56:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204928, encodeId=dd4e20492868, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed May 31 21:41:31 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312292, encodeId=cdf81312292fe, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue May 30 08:56:00 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2017-05-30 Homburg

    #miRNA#

    0

相关资讯

CLIN CNACER RES：Foretinib一线治疗晚期肝细胞癌临床试验结果

Foretinib是一种口服MET、ROS、RON、AXL、TIE-2、VEGFR2多激酶抑制剂。CLIN CANCER RES近期报道了一篇文章，研究Foretinib一线治疗晚期肝细胞癌的治疗效果。

Hepatology：乙醛脱氢酶2通过调节AMPK通路抑制肝细胞癌进展

背景：对于肝细胞癌患者而言，迫切需要可预测预后且可作为治疗靶点的潜在生物标记物。方法：为满足这一需求，我们通过筛查来识别在转录组学和蛋白组学水平同肝细胞癌发生及进展相关的功能基因。结果：乙醛脱氢酶-2（ALDH2）被作为兴趣基因进行进一步研究。同正常组织相比，肿瘤组织的ALDH2的mRNA和蛋白水平显着降低，在迁徙能力更强的组织中其水平更低。临床相关性研究提示ALDH2同存活率及多发迁徙相关的临床

Gastroenterol：一种驱虫药有望高效地治疗肝细胞癌

作为一种与肝病和肝硬化相关联的癌症，肝细胞癌（HCC）经常在晚期时才表现出症状。在全世界，它是癌症死亡的第二大原因，但是迄今为止，它并没有一种有效的疗法。 美国加州大学旧金山分校计算健康科学研究所主任Atul Butte博士说，正如没有治疗方法的其他疾病那样，需要理解和治疗这种癌

Gur：肝细胞癌进展的新机制！

染色体不稳定（CIN）是基因组不稳定的最常见形式，其通过增强肿瘤异质性、耐药性和免疫逃逸促进肝细胞癌（HCC）的进展。CIN本身是DNA损伤的重要因素，维持结构染色体异常，但其潜在的机制尚未可知。近期，一项发表在杂志GUT上的研究使用二乙基亚硝胺诱导的HCC动物模型评估了DNA损伤反应蛋白检查点激酶2（Chk2）的表达。Chk2同时也在两个人类肝癌样本队列中确定。为了评估Chk2的功能作用，通过使

ASCO2017：索拉非尼在晚期肝细胞癌患者中的多中心II期研究

在早期剂量递增研究中，索拉非尼是一种新的口服多激酶抑制剂，在0.2g bid和0.3g bid剂量水平下对治疗不同类型实体瘤包括HCC均显示出抗肿瘤活性和良好耐受性。 这项前瞻性研究旨在评估索拉非尼在晚期HCC患者中的安全性和有效性。

JAMA SURGERY：肝切除术后残余肝组织缺血与肝细胞癌早期复发及不良预后有关

肝切除术后残余肝可能会出现血供不足，尤其是进行非解剖性切除以及存在血管损伤的残余肝，血供不足的情况更为严重。JAMA SURGERY近期报道了一篇文章，评估残余肝缺血（RLI）对于肝细胞癌患者肝切除术后长期生存及死亡率的影响。